Figure 1. Cost-effectiveness ratio for patients with Philadelphia chromosome-positive acute leukemia and FLT3-mutated AML treated with stem cell transplantation, chemotherapy, and molecular targeting agents. (a) The CERs for Ph+ AL treated with SCT, CT, dasatinib (D), and ponatinib (P) were $322,375, $34,928, $61,104, and $46,234, respectively. (b) The CERs for FLT3-AML treated with SCT, CT, gilteritinib (G), and quizartinib (Q) were $355,270, $42,717, $94,987, and $90,080, respectively. CER: cost-effectiveness ratio; CR: cytotoxic chemotherapy; FLT3: FMS-like tyrosine kinase 3; FLT3-AML: FLT3-mutated acute myeloid leukemia; Ph+ AL: Philadelphia chromosome-positive acute leukemia; SCT: stem cell transplantation